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 Summary
Transdermal therapeutic systems (TTS) belong to the widely used methods of drug administration, which allow 
rate-controlled drug delivery and avoidance of first-pass metabolism in the liver. Beside scopolamine, nitroglycerin 
(glyceryl trinitrate), nicotine, clonidine and fentanyl, also transdermal delivery of sex steroids for hormone 
replacement therapy and contraception is a well-known and popular method in daily clinical practice. It is estimated 
that approximately 20% of patients using transdermal estradiol may complain of adverse cutaneous side effects. 
Most of those reactions are mild or moderate, usually limited to the area of drug application. However, prolonged 
use may increase the chance of developing sensitization. 
The purpose of this review is to provide up-to date information on the spectrum of cutaneous reactions caused 
by TTS and the characteristics of potential contact allergens, including sex hormones. Proper management and 
prophylactic measures were also included.
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Introduction
Transdermal	therapeutic	systems	(TTS)	are	characterized	by	
adhesive-containing	 systems,	 with	 a	 defined	 surface	 area,	 that	
deliver	drug	to	skin	at	a	controlled	rate.	Each	TTS	has	three	main	
components:	
-	active	medication,	
-	adhesive	material,
-	enhancing	agents.	
Several	 types	 of	 TTS	 are	 currently	 available,	 and	 they	
include	matrix,	local-action	transcutaneous,	and	reservoir	TTSs.	
Matrix	TTS	is	considered	 the	most	common	type	and	contains	
a	 single-layer	mixture	of	 adhesive,	 active	 ingredient	 and	other	
components,	that	is	directly	adjacent	to	the	skin	surface.	So-called	
local-action	transcutaneous	TTS	is	used	to	deliver	nonsteroidal	
anti-inflammatory	 drugs	 (NSAIDs)	 through	 the	 skin	 and	 it	 is	
similar	to	the	matrix	TTS,	except	a	nonwoven	polyester	backing	
supporting	NSAIDs	formulation.	A	reservoir	TTS	is	composed	
of	 a	 depot	 of	 liquid	 containing	 an	 active	 ingredient,	 attributed	
with	 permeation	 enhancer,	 which	 is	 released	 through	 a	 rate-
controlling	membrane	[1].	
Newer	methods	 of	 drug	 delivery	 through	 the	 skin	 include	
also:	programmable	battery-powered	carbon	nanotube	membrane	
TTS	and	transdermal	microneedle	TTS	[2,	3,	4].	
Characteristics of possible hypersensitivity 
reactions to TTS
Irritant contact dermatitis (ICD)	 is	 defined	 as	 an	
inflammatory	 reaction	 to	 various	 external	 agents	 with	 an	
activation	of	various	inflammatory	and	immunologic	mediators,	
however	 with	 no	 involvement	 of	 memory	 T	 cells	 or	 antigen-	
specific	immunoglobulins.	
ICD	is	usually	described	as	a	transient,	mild	or	moderate	type	
of	reaction.	An	exact	prevalence	of	ICD	is	unknown,	however	is	
considered	 to	 be	 the	most	 common	 cutaneous	 reaction	 among	
TTS	users	and	estimated	to	be	present	in	up	to	97%	of	subjects	
[3,	4].
Clinical	 picture	 of	 ICD	 includes	 sharply	 demarcated	
erythema,	vesicles	and	scaling,	usually	with	concomitant	pruritus,	
burning	or	stinging	sensation.	ICD	is	most	commonly	reported	
with	reservoir	TTSs.	Most	irritant	reactions	are	localized	to	the	
site	of	application	and	resolve	spontaneously	within	several	days	
of	 TTS	 removal	 –	 this	 is	 often	 described	 as	 a	 “decrescendo”	
reaction	pattern	[2].
Ingredients	 commonly	 implicated	 in	 ICD	 include	 ethanol	
and	glycerin.	Bacterial	degradation	of	nitroglycerin	may	 result	
in	production	of	acrylic	aldehyde,	which	is	also	another	known	
irritant.	 TTS	 delivery	 systems	 are	 designed	 to	 be	 applied	 to	
the	 skin	 for	 prolonged	 periods	 of	 time.	 Taking	 this	 fact	 into	
consideration,	 sweat	 accumulation	 is	 thought	 to	 be	 one	 of	 the	
major	 factors	 in	 skin	 irritation	 with	 long-term	 applications	 of	
TTSs.	Skin	occlusion	can	lead	to	the	obstruction	of	sweat	ducts	
with	subsequent	escape	of	sweat	from	the	duct	within	 the	skin	
resulting	in	inflammation	and	pruritus.	Yeast	and	bacteria	growth	
may	 additionally	 be	 promoted	 in	 the	 moist	 high-temperature	
environment	and	can	also	play	a	minor	role	in	ICD	from	TTS.	
Another	possible	additional	irritant	is	friction	from	the	repeated	
removal	of	the	patch.	It	has	to	be	emphasized,	that	most	patients	
continue	 to	 use	 the	 TTS	 despite	 described	 skin	 problems	 [6-
9].	 In	 some	cases	vasodilatation	can	mimic	 irritation.	Swedish	
researchers	 described	 a	 patient	 presenting	 with	 erythema	 and	
pruritus	 after	 the	 application	 of	 a	 nicotine	 TTS.	 Patch	 testing	
revealed	erythematous	reaction	to	nicotine	but	with	no	papules,	
edema,	or	vesicles	–	what	could	be	due	not	 to	contact	 allergy,	
but	rather	to	vasodilatation	which	is	a	known	effect	of	nicotine	
[10,	11].
Allergic contact dermatitis (ACD)	is	on	the	other	hand	a	
relatively	rare	phenomenon	and	regards	only	selected	number	of	
patients.	ACD	represents	a	type	IV	cell-mediated	hypersensitivity	
reaction	 (delayed	 type	 hypersensitivity)	 according	 to	 the	
classification	 of	 Gell	 and	 Coombs	 [12,	 13,	 14].	 Occlusive	
character	 of	TTS	 and	 its	 irritant	 capacity	 provides	 an	 optimal	
environment	for	sensitization	and	moreover,	prolonged	use	of	a	
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patch	 increases	 the	chance	of	developing	contact	 sensitization.	
The	first	phase	of	the	type	IV	reaction	is	a	sensitization	phase	-	a	
7-	to	14-day	process	that	must	occur	prior	to	the	development	of	
cutaneous	allergy.	Once	the	allergic	reactivity	is	established,	the	
second	phase	is	elicitation	-	re-exposure	to	contact	allergen	leads	
to	ACD	within	hours	to	days	at	sites	of	recent	TTS	application.	
ACD	has	been	reported	in	up	to	25%	of	clonidine	TTS	users,	up	
to	3%	in	nicotine	TTS	trials,	and	up	to	10%	with	scopolamine	
TTS	use.	The	 reaction	has	 also	been	described	 in	 case	 reports	
with	the	use	of	nitroglycerin,	testosterone,	estradiol,	and	fentanyl	
TTSs	[3,	15-17].	
Symptoms	 of	 ACD	 may	 appear	 even	 after	 many	 years	
of	 continuous	 exposure	 to	 the	 patch.	 Potential	 allergens	 in	
a	 TTS	 include	 the	 adhesive,	 the	 membrane,	 the	 solvent,	
the	 enhancer,	 and	 an	 active	 medication.	 ACD	 presents	 with	
intense	 erythema,	 pruritic	 inflammatory	 papules	 and	 vesicles	
(which	may	then	rupture	producing	erosions).	In	some	patients	
secondary	 dissemination	 of	 skin	 lesions	 is	 possible,	 which	 is	
called	 ‘secondary	 allergisation’.	 ACD	 may	 be	 complicated	
by	 the	 development	 of	 postinflammatory	 hyperpigmentation	
and	 secondary	 superinfection	 with	 bacteria.	 Natural	 course	 of	
ACD	 is	 characterized	by	complete	 resolution	once	 responsible	
allergen	has	been	removed	from	contact	with	the	skin.	Unlike	in	
ICD	patients,	ACD	typically	shows	a	“crescendo”	pattern:	skin	
reaction	tends	to	worsen	in	the	days	after	TTS	removal	and	may	
then	persist	for	over	three	weeks.	Furthermore,	a	re-exposure	to	
an	allergen	at	a	new	localization	may	result	in	a	flare	of	dermatitis	
at	the	previous	site,	in	addition	to	ACD	at	the	new	site	[3].
Other	potential	contact	allergens	included	in	TTS	apart	of	an	
active	medication	include:
- peppermint and menthol: peppermint	and	menthol	may	
be	added	 to	TTS	due	 to	 their	 anesthetic	properties	 and	also	 to	
enhance	dilation	of	the	vessels	and	subsequent	drug	penetration	
[18].	It	has	to	be	emphasized,	that	menthol	is	considered	a	rare	
sensitizer	but	is	likely	to	undergo	metabolism	to	menthone,	which	
then	may	induce	contact	sensitization.
- hydroxypropyl cellulose: pruritus,	erythema,	edema,	and	
postinflammatory	 hyperpigmentation	 have	 been	 described	 at	
sites	where	an	estradiol	TTS	containing	hydroxypropyl	cellulose,	
estradiol,	 and	 alcohol	 was	 applied.	 Subsequent	 allergological	
testing	 with	 mentioned	 components	 revealed	 positive	 results	
for	hydroxypropyl	cellulose	in	70%	ethanol	and	hydroxypropyl	
cellulose	 in	mineral	 oil	 and	 negative	 results	 for	 70%	 ethanol,	
mineral	 oil,	 and	 hydroxypropyl	 cellulose	 in	 water.	 Described	
patient	 presented	 with	 a	 negative	 result	 for	 hydroxypropyl	
cellulose	 in	water,	 and	 that	 is	why	 in	 authors’	 opinion	vehicle	
seems	 important	 for	 allergen	 penetration	 and	 potential	
sensitization	[19].	
- ethanol: generally, ethanol	is	considered	as	a	potent	irritant,	
but	 ethanol	 contact	 allergy	 is	 rare	 and	 often	 misdiagnosed.	
Patients	 who	 are	 topically	 sensitized	 to	 ethanol	 may	 develop	
local	 and	 generalized	 dermatitis	 as	 a	 result	 of	 consumption	 of	
alcoholic	 beverages.	 There	 are	 reports	 on	 patients,	 who	 were	
using	 estradiol	 TTSs	 to	 treat	 menstrual	 headaches	 and	 who	
presented	with	pruritic	erythematous	lesions	at	TTS	application	
sites.	 Patch	 testing	 revealed	 positive	 results	 ethanol,	 TTS	
with	ethanol	 and	no	estradiol,	TTS	with	ethanol	 and	estradiol,	
and	 hydroxypropyl	 cellulose	 in	 ethanol.	 Occlusion	 may	 have	
promoted	the	sensitization	[20-24].
- adhesives: there are several publications, implicating 
adhesives	as	contact	allergens;	in	most	cases,	patch	testing	served	
as	a	helpful	tool	in	identification	of	the	suspected	substance	[25-
27].	
The	diagnosis	of	ACD	may	be	confirmed	by	identifying	the	
causative	 allergen	 with	 the	 use	 of	 patch	 testing.	 Patch	 testing	
involves	occlusion	of	various	diluted	allergens	on	the	skin	of	the	
back	 for	48	hours.	After	patch	 test	 removal,	 the	patient	has	 to	
return	 also	24	hours	 later	 for	 a	 second	 reading.	 In	 some	cases	
additional	 reading	may	 be	 advised	 (96	 hours	 and	 7	 days	 after	
testing).	A	positive	reaction	is	defined	as	edematous,	erythematous	
and	possibly	vesicular	plaque	at	the	site	of	allergen	application	
[3,	12,	13].	
Other types of reactions
Allergic	 contact	 urticaria	 (ACU)	 is	 an	 important,	
although	 rare	possible	 reaction	 to	TTS.	ACU	represents	 type	 I	
hypersensitivity	reaction	according	to	Gell	and	Coombs	[14],	with	
IgE-mediated	inflammatory	response	to	a	specific	allergen.	This	
type	of	immediate	reaction	occurs	within	minutes	of	application	
of	an	allergen	and	clinically	presents	as	wheals	and	concomitant	
marked	 pruritus.	 Generalized	 urticaria,	 angioedema,	 and	 even	
anaphylaxis	may	develop.	ACU	has	been	mainly	described	with	
the	use	of	nicotine	or	nitroglycerin	TTS.	Diagnostic	procedures	
in	 ACU	 include	 prick	 testing:	 Morrow-Brown	 lancet	 is	 used	
to	 prick	 through	 a	 drop	 of	 diluted	 suspected	 allergen	 into	 the	
dermis.	 Positive	 reaction	 occurs	 within	 15-20	 minutes	 and	 is	
defined	 as	 a	 wheal	 of	 a	 diameter	 at	 least	 equal	 to	 the	 size	 of	
positive	histamine	control	wheal.	Some	individuals	also	present	
symptoms	of	dermatographism,	a	condition	in	which	pressure	or	
friction	against	 the	skin	may	produce	urticarial	(usually	 linear)	
response.	 Predisposed	 patients	 may	 develop	 a	 dermatographic	
response	from	the	pressure	of	an	adhesive	patch	and/or	from	the	
friction	that	occurs	during	removal	of	the	patch	or	dressing	[3].
Hypersensitivity to estrogen in TTS  
– review of literature data
Koch	presented	a	50-year-old	postmenopausal	woman	with	a	
history	of	discoid	indurated	erythema	at	a	site	of	patch	containing	
5	 mg	 estradiol	 and	 15mg	 norethisterone.	 Itchy	 skin	 lesions	
appeared	 on	 third	 application	 and	 then	 progressed	 into	 bullae.	
Due	 to	 the	 reaction,	 patient	 was	 transitioned	 to	 an	 estradiol-
containing	 gel,	 which	 also	 resulted	 in	 local	 acute	 eczematous	
eruption.	Patient	was	patch	tested	with	separate	components	of	
the	TTS	(in	1%	concentration	 in	ethanol)	and	gel.	Diagnostics	
revealed	strongly	positive	reaction	to	both	hormones	contained	
in	 TTS	 [28].	 Similar	 case	 description	 provide	 Corazza	 et	 al.,	
who	 reported	 on	 a	 47-year-old,	 postmenopausal	 woman	 who	
had	eczematous	reaction	after		use	of	estradiol	in	TTS	as	well	as	
gel	application.	What	 is	more,	patient	also	developed	systemic	
pruritic	eruption	after	switching	her	to	oral	estrogen	therapy.	In	
this	case	type	IV	of	allergic	reaction	to	transdermal	estradiol	and	
gel	were	confirmed	in	patch	tests,	also	the	verification	of	systemic	
contact	dermatitis	was	performed	[29].	Another	case	of	systemic	
sensitization	 to	 17	 beta-estradiol	 induced	 by	 transcutaneous	
application	was	introduced	by	El	Sayed	et	al.	[30].	Alfaya	et	al.	
reported	a	case	of	20-year-old	woman	with	contact	allergy	to	TTS	
contraceptives	 containing	 ethinylestradiol	 and	 norelgestromin	
after	using	them	for	2	months.	As	an	alternative,	oral	therapy	was	
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offered	with	a	good	 tolerance	[31].	Contact	dermatitis	 reaction	
was	also	detected	in	15-year-old	adolescent,	who	used	transdermal	
patch	as	a	contraceptive	and	after	5	months	developed	intensely	
inflammatory	 reaction	within	 the	 site	 of	 application.	However,	
allergic	background	was	not	confirmed	in	patch	test	[32].
On	 the	 other	 hand,	 Boehncke	 et	 al.	 described	 a	 woman	
treated	initially	with	oral	estradiol	without	any	skin	changes	and	
then	 patient	was	 switched	 to	 estradiol	 in	TTS,	what	 provoked	
the	eczema.	The	erythema	within	the	site	of	plaster	application	
was	visible	 on	 the	ninth	day	of	 therapy	 and	 then	 evolved	 into	
formation	 of	 generalized	 urticarial	 lesions.	 Patient	 was	 patch	
tested	and	positive	reactions	to	estradiol-17	beta	1%,	2%	and	4%	
in	ethanol	were	recorded	[33].
Most	 of	 the	 presented	 literature	 data	 concern	 ACD	 to	
estradiol,	but	there	are	also	reports	on	the	reaction	to	the	adhesive	
and	to	the	component	of	the	reservoir	(hydroxypropyl	cellulose	
component)	[19,	34].	The	possibility	of	cross-reactions	between	
hydroxypropyl	 cellulose	and	 the	 ingredient	of	 acyclovir	 cream	
were	 also	 observed	 and	 should	 be	 taken	 into	 consideration	
[35].	Researchers	from	UK	indicate	also	the	potential	of	cross-
reactions	between	sex	steroids	and	topical	glucocorticosteroids.	
They	 present	 a	 case	 of	 61-year-old	woman	with	 chronic	 hand	
and	 food	 dermatitis	 and	 concomitant	 allergy	 to	 estradiol	 and	
norethisterone	and	numerous	topical	steroids	[36].
Recently,	 systemic	 photosensitivity	 due	 to	 contraceptive	
patch	 was	 described.	 Gomez-Bernal	 et	 al.	 presented	 a	 case	
report	of	a	35-year-old	woman	who	developed	3	episodes	of	a	
prurigionous	 papulovesicular	 eruption	 during	 the	 3-year	 long	
use	 of	 ethinyloestradiol	 and	 norelgestromin.	 Discontinuation	
of	 contraceptive	 TTS	 was	 advised	 and	 3	 months	 later	 oral	
contraceptives	 were	 prescribed,	 which	 also	 provoked	 skin	
symptoms.	 Photobiological	 examination	 confirmed	 systemic	
photosensitivity	 [37].	 To	 diagnose	 photosensitivity	 reaction	
photopatch	tests	are	a	very	useful	method	[38].
The	problem	of	adverse	skin	reactions	to	transdermal	estradiol	
are	mainly	accentuated	in	warm	humid	climates.	In	a	study	from	
Mexico,	 45	 patients	were	 investigated	 in	 regards	 of	 	 potential	
side	effects	during	the	use	of	TTS	and	22,2%	discontinued	the	
therapy	 because	 of	 severe	 skin	 reactions	 characterized	mostly	
as	 eczematous	 skin	 lesions	 associated	 with	 persistent	 itching	
[38].	Frenkel	et	al.	provide	data	from	Israel,	in	which	severe	skin	
reactions	mainly	in	the	form	of	erythema	were	noticed	and	led	
to	withdrawal	of	treatment	in	17,5%	cases	[40].	In	both	studies	
patch	tests	were	not	performed	[39,	40].
Management and prevention of TTS 
cutaneous hypersensitivity
The	 patient	 should	 be	 informed	 that	 mild	 to	 moderate	
erythema	 may	 be	 observed	 at	 the	 time	 of	 TTS	 removal	 and	
has	already	been	 reported	 in	various	clinical	studies.	 If	 ICD	is	
suspected,	 usually	 use	 of	 emollients	 may	 provide	 temporary	
relief	at	previous	patch	application	sites.	If	the	severity	of	ICD	
is	 high	 and	 the	 reaction	 is	 unresponsive	 to	 emollients,	 twice-
daily	application	of	a	low-potency	topical	glucocorticosteroid	is	
advisable,	however	continuous	application	of	glucocorticosteroid	
preparation	 at	 the	 same	 site	 without	 resolution	 for	 more	 than	
three	weeks	should	be	avoided.
As	in	other	potential	drug	hypersensitivity	reactions,	also	in	
suspected	hypersensitivity	to	TTS	a	detailed	history	is	the	main	
point	 of	 the	management.	 If	 a	TTS-related	ACD	 is	 suspected,	
discontinuation	 of	 treatment	 is	 the	most	 important	 element	 of	
reaction	 management.	After	 discontinuation,	 treatment	 with	 a	
medium-strength	to	potent	topical	glucucorticosteroid	ointment	
applied	 twice	 daily	 is	 usually	 sufficient.	 Oral	 antihistamines	
help	 to	 alleviate	 pruritus.	 The	 patient	 should	 be	 referred	 to	 a	
dermatologist	 for	 consultation	 and	 patch	 testing	 after	 ACD	
resolves	[2,	3,	5,	8].
The	patient	has	to	follow	manufacturers’	recommendations	
regarding	 site	 of	 application	 as	 it	 is	 crucial	 for	 effectiveness	
of	 the	 medication.	 However,	 alternating	 application	 sites	 is	
one	 of	 the	 most	 important	 preventive	 measures	 against	 TTS	
hypersensitivity.		It	is	best	to	develop	a	rotational	system	for	the	
area	of	patch	application.
Another	 significant	 element	 is	 maintenance	 of	 the	 skin	
barrier	function	and	avoidance	of	irritants.	Proper	and	skin	care	is	
needed:	baths	and	showers	should	be	limited	to	5-10	minutes	and	
emollients	should	be	used	for	bathing	and	after-bath	regular	skin	
moisturization.	 Due	 to	 well-known	 potential	 for	 irritation	 and	
disturbance	of	skin	barrier	isopropyl	alcohol	and	acetone	should	
not	be	used	for	wiping	the	skin.	Patches	should	be	removed	gently,	
and	scrubbing	of	the	site	to	remove	any	residual	adhesive	should	
be	avoided.	An	oil-based	product	(petroleum	jelly,	mineral	oil)	
can	be	used	to	loosen	any	residual	adhesive.	One	of	the	possible	
preventive	measures	against	contact	sensitization	to	TTS	is	a	co-
administration	 of	 topical	 glucocorticosteroids.	 Pre-medication	
with	a	glucocorticosteroid	preparation	has	been	shown	to	lessen	
the	incidence	and	severity	of	skin	irritation.	
However,	well-known	adverse	effects	of	 long	 term	topical	
corticosteroid	 administration	 may	 limit	 this	 strategy.	 That	 is	
why	improving	predictive	testing	for	the	potential	development	
of	cutaneous	hypersensitivity	to	drugs	and	other	components	of	
TTS	 is	 undoubtedly	 an	 important	 task	 for	 the	 research	 groups	
worldwide	[2,	3,	5,	8,	41-43].
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